COVID-19 Outcomes in Pediatric Patients With Atopic Dermatitis: A Multicenter Analysis

Raiker, Rahul; Pakhchanian, Haig; Jenkins, Kendall; Shen, Lisa Y

doi:10.1097/der.0000000000000881

Cited by 4 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, others reported that patients with atopic dermatitis do not have a significantly increased risk of SARS-CoV-2 infection [ 41 ]. On the other hand, the risk of COVID-19-related hospitalization was significantly lower in children with atopic dermatitis, compared with those without atopic dermatitis, with no differences noted in the prevalence of COVID-19-related severity and critical care admission [ 42 ]. These findings underline the complex relation among SARS-CoV-2 infection, COVID-19 outcomes, and atopic dermatitis.…”

Section: Atopic Dermatitismentioning

confidence: 99%

“…Furthermore, concern exists regarding the effects of medications used to treat atopic dermatitis on SARS-CoV-2 infection and COVID-19 outcomes. Treatment with methotrexate for 1 year was not associated with severe COVID-19, COVID-19-related hospitalization, or critical care admission among children [ 42 ]. However, use of systemic corticosteroids for 1 year was associated with an increased risk of COVID-19-related hospitalization [ 42 ].…”

Section: Atopic Dermatitismentioning

confidence: 99%

“…Treatment with methotrexate for 1 year was not associated with severe COVID-19, COVID-19-related hospitalization, or critical care admission among children [ 42 ]. However, use of systemic corticosteroids for 1 year was associated with an increased risk of COVID-19-related hospitalization [ 42 ]. Even during the COVID-19 pandemic, well-controlled status of atopic dermatitis with appropriate medication is important for its proper management.…”

Section: Atopic Dermatitismentioning

confidence: 99%

See 2 more Smart Citations

Management of patients with allergic diseases in the era of COVID-19

Lee¹

2022

Clin Exp Pediatr

View full text Add to dashboard Cite

In the early days of the coronavirus disease 2019 (COVID-19) pandemic, allergic diseases, especially asthma, were considered to be risk factors for severe COVID-19 infection, hospitalization, and death. These concerns stemmed from the idea that individuals with allergic diseases are generally more susceptible to respiratory virus infections, which are major causes of exacerbation of allergic diseases.However, epidemiologic data with mechanistic studies showed that the associations between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes of allergic diseases are complex and affected by diverse factors such as allergic disease severity, phenotypes, and control status with current medications. In addition, children generally have less severe clinical outcomes of COVID-19 than those of adults, which complicates the association between allergic diseases and COVID-19-related outcomes among them. The present review summarizes the potential association between allergic diseases and COVID-19-related outcomes and discusses the factors requiring consideration. The findings viewed herein will aid the management of allergic diseases in patients with SARS-CoV-2 infection and the establishment of medical polices for managing patients with allergic diseases.

show abstract

Section: Atopic Dermatitismentioning

confidence: 99%

Section: Atopic Dermatitismentioning

confidence: 99%

Section: Atopic Dermatitismentioning

confidence: 99%

See 1 more Smart Citation

Management of patients with allergic diseases in the era of COVID-19

Lee¹

2022

Clin Exp Pediatr

View full text Add to dashboard Cite

show abstract

“…The continuous use of topical steroids as well as biologics such as dupilumab leads to better disease outcomes regardless of the presence of COVID-19. 13) However, the use of systemic corticosteroids for 1 year reportedly increases one's risk of COVID-19related hospitalization. 13) SARS-CoV-2 is currently widespread and significantly less fatal than it was in 2020.…”

Section: Diseasesmentioning

confidence: 99%

“…The most part of managing AD involves maintaining skin hydration, removing exacerbating factors, and applying appropriate medications despite the COVID-19 pandemic. The continuous use of topical steroids as well as biologics such as dupilumab leads to better disease outcomes regardless of the presence of COVID-19 [ 13 ]. However, the use of systemic corticosteroids for 1 year reportedly increases one’s risk of COVID-19-related hospitalization [ 13 ].…”

mentioning

confidence: 99%